Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
| Revenue (TTM) | $324.97M |
| Gross Profit (TTM) | $157.29M |
| EBITDA | $-259.60M |
| Operating Margin | -52.30% |
| Return on Equity | -40.40% |
| Return on Assets | -20.30% |
| Revenue/Share (TTM) | $0.79 |
| Book Value | $1.63 |
| Price-to-Book | 5.46 |
| Price-to-Sales (TTM) | 12.25 |
| EV/Revenue | 11.94 |
| EV/EBITDA | -8.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 65.70% |
| Shares Outstanding | $452.97M |
| Float | $394.33M |
| % Insiders | 0.35% |
| % Institutions | 70.61% |
Volatility is currently contracting
SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 20, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 240,135 shares of Iovance's common stock to twenty new, non-executive employees.
Does Iovance Biotherapeutics (IOVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Iovance Biotherapeutics, Inc. delivered a breakout Q2 '26 for Amtagvi sales, with management guiding for further growth ahead. IOVA's maturing clinical pipeline and imminent NSCLC readout position the company for further upside, given the market potential in NSCLC is several times larger than in melanoma. Potential competitor, IMTX, is expecting to produce results from a trial of its cell therapy, Anzu-cel, in melanoma in H1 '27.
Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.
The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Iovance Biotherapeutics NASDAQ: IOVA reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic cancers.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IOVA and any ticker you trade — then tracks every position and per-strategy win rate.
